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Abstract
Objectives Prolidase is a member of the matrix metallo-
proteinase family. It plays a major role in collagen turn-
over, matrix remodeling and cell growth. Nitric oxide (NO)
regulates many processes such as collagen synthesis and
matrix remodeling. Thus, NO may augment angiogenesis,
tumor invasion, and metastasis. The aim of this study was
to investigate total antioxidant status (TAS), malondialde-
hyde (MDA) and NO levels in patients with bladder cancer
and to determine their relationship with prolidase activity.
Design and methods Thirty-ﬁve patients with bladder
cancer and 32 controls were enrolled. Serum TAS, MDA,
prolidase activity and NO levels were determined.
Results Serum prolidase activity, NO levels and MDA
levels were signiﬁcantly higher in bladder cancer than
controls (all, P\0.05), while TAS levels were signiﬁ-
cantly lower (P\0.05).
Conclusions Our results show that increased prolidase
seems to be associated with increased NO levels and oxi-
dative stress along with decreased antioxidant levels in
bladder cancer.
Keywords Bladder cancer  Nitric oxide  Total
antioxidant status  Malondialdehyde  Prolidase activity
Introduction
Bladder cancer is a common tumor of the urinary tract
(Macvicar 2000). It is the fourth most common type of
cancer in men in the United States. The most common risk
factors for bladder cancer are exposure to industrial car-
cinogens, cigarette smoking, male gender, and possibly diet
(Wynder and Goldsmith 1977; Zeegers et al. 2004).
Another major etiological factor is infestation by the par-
asite Schistosoma hematobium (Wynder and Goldsmith
1977).
Reactive oxygen species (ROS) have been implicated in
the pathogenesis of various diseases, including cancers
(Templar et al. 1999). There is strong evidence linking
oxidative stress and bladder cancer in literature (Yalcin
et al. 2004). In previous studies, it has been demonstrated
that ROS are directly suggested in oxidative damage of
cellular macromolecules such as lipids, proteins, and
nucleic acids in tissues (Batcioglu et al. 2006). Moreover,
oxidative stress can lead to tumor angiogenesis. It also has
been reported that ROS can also augment tumor cell
migration, increasing the risk of invasion and metastasis
(Nishikawa 2008).
Nitric oxide (NO) is generated by the enzyme family of
nitric oxide synthases (NOS). NO is expressed in a wide
range of mammalian cells as macrophages, hepatocytes,
and endothelial cells (Knowles and Moncada 1994). It is a
short-lived free radical, a pleiotropic biomolecule, critical
to several biological processes (Koshland 1993). NO has
been suggested to play an important role in tumor biology
with both facilitatory and inhibitory effects on tumor
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DOI 10.1007/s00432-011-1136-4growth (Wolf et al. 2000). Also, NO has many implications
as a potential regulatory effector for prolidase and NO may
regulate the activity of metalloproteinases (MMPs; Tsuru-
da et al. 2004). Although prolidase is a special type of
MMP, it may be also regulated by NO because it catalyzes
the terminal step in matrix breakdown (Tsuruda et al.
2004).
The extracellular matrix (ECM) consists of collagens,
proteoglycans, and glycoproteins. During inﬂammation and
cancer invasion, ECM is degraded by MMPs, resulting in
the release of a large amount of peptides containing proline
and hydroxyproline (Surazynski et al. 2008). Among the
MMPs, prolidase is a manganese-dependent cytosolic
exopeptidase, and it cleaving imidodipeptides and imido-
tripeptides with C-terminal proline or hydroxyproline
(Myara et al. 1984). Its activity has been documented in
erythrocytes, leukocytes, plasma, dermal ﬁbroblasts, the
kidney, brain, heart, thymus, and uterus (Liu et al. 2007).
One of the consequences of neoplastic transformation is
deregulation of tissue collagen metabolism. The ﬁnal step
of collagen degradation is mediated by prolidase (Sura-
zynski et al. 2008; Palka et al. 2002). Prolidase activity has
been investigated in various malignant tumors including
pancreas cancer (Palka et al. 2002), lung adenocarcinoma
(Karna et al. 2000), breast cancer (Cechowska-Pasko et al.
2006), endometrial cancer (Arioz et al. 2009), stomach
cancer (Guszczyn and Sobolewski 2004), and ovarian
cancer (Camuzcuoglu et al. 2009). However, to the best of
our knowledge, serum prolidase enzyme activity has not
been evaluated in patients with bladder cancer.
Therefore, the aim of this study was to investigate serum
total antioxidant status (TAS), malondialdehyde (MDA)
and NO levels in patients with bladder cancer and to
determine their relationship with serum prolidase enzyme
activity.
Methods
Subjects
Thirty-ﬁve (mean age of 63.54 ± 3.4) men patients with
bladder cancer were enrolled in the present a cross-sectional
study.Allthepatientswerelifetimenon-smokersandfreeof
drug,alcohol,antioxidantsupplementconsumption,andany
metabolic disease. None of the patients had any other sig-
niﬁcant disease or malignancies except bladder cancer and
only the newly diagnosed patients with no prior chemo-
therapeutic treatment were included in this study.
Controls consisted of 32 healthy men of age 62.76 ± 4.8
randomly selected from a group of healthy non-smoking
volunteers with no history of previous disease, drug,
antioxidant agents or alcohol consumption.
The patient and control groups were of similar socio-
economic status. As for tumor staging, 28 patients were
diagnosed with non-invasive tumor (Ta–T1) where as 7
patients with invasive tumor (T2–T4). Patients were clas-
siﬁed into three groups with respect to tumor grading
where 21 patients had well differentiated (G1), 9 had
intermediate (G2), and 5 had poorly differentiated (G3)
tumors. The superﬁcial urothelial papillary tumors were
graded according to the 2004 World Heath Organization
(WHO) grading system into low-grade and high-grade
papillary neoplasms.
The study protocol was carried out in accordance with
the Helsinki Declaration as revised in 2000. All partici-
pants were informed about the study protocol and the
written consent was obtained from each one.
Blood collection
Following 12 h of fasting period, blood samples were
obtained in the morning. Blood samples were collected into
empty tubes and immediately stored on ice at 4C. The
serum was then separated from the cells by centrifugation
at 3,000 rpm for 10 min. Serum samples for the measure-
ment of prolidase activity, TAS, NO and MDA levels were
stored at -20C until they were used.
Measurement of total antioxidant status
Serum TAS was determined using an automated mea-
surement method, developed by Erel (2004). The results
are expressed as mmol Trolox Equiv./l.
Measurement of serum lipid peroxidation
Serum lipid peroxidation was measured by estimating
malondialdehyde (MDA) levels from serum as described
by Yoshioka et al. The results are expressed as nmol/ml
(Yoshioka et al. 1979).
Determination of prolidase activity
The serum prolidase activity was determined according to
the method of Myara et al. (Myara et al. 1982), based on
the measurement of proline by Chinard’s reagent (Chinard
1952). The results are expressed as U/l.
Measurement of serum nitric oxide
Serum NO2
-/NO3
- concentrations were determined using
the Griess reaction according to Tracey et al. (Tracey et al.
1995). The results were expressed as lmol/l.
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All the results are expressed as means and standard devi-
ation (mean ± SD). Non-parametric continuous variables
were compared by Mann–Whitney U test. Parametric
variables were compared using Student’s t test. P value less
than 0.05 was considered as statistically signiﬁcant. Sta-
tistical evaluation was carried out with the SPSS 11.0.
Results
The demographic and clinical data of bladder cancer and
control groups are shown in Table 1. There were no sta-
tistically signiﬁcant differences between bladder cancer
patients and controls in respect to age and BMI (all
P[0.05; Table 1).
Serum prolidase activity, NO levels, and MDA levels
were signiﬁcantly higher in bladder cancer than controls
(all, P\0.05), while TAS levels were signiﬁcantly lower
(P\0.05; Table 2).
No correlation was observed between tumor grading,
and serum prolidase activity, NO, MDA levels and TAS
levels (P[0.05).
Discussion
Collagen is major extracellular matrix component in vari-
ous tissues, including kidney. It has been demonstrated that
the human non-compliant bladder is characterized
histologically by an increased deposition of ECM protein,
especially type III collagen, in the muscle wall (Kaplan
et al. 1997). Prolidase is a homodimeric iminodipeptidase
that releases carboxy-terminal proline or hydroxyproline
from oligopeptides. It plays a major role in collagen turn-
over, matrix remodeling and cell growth (Jackson et al.
1975). The primary biological function of prolidase
enzyme in humans appears to involve the metabolism of
collagen degradation products and the recycling of proline
from dipeptides for collagen resynthesis (Surazynski et al.
2008). Moreover, it has been suggested that the prolidase
enzyme activity may be a rate-limiting factor in the regu-
lation of collagen biosynthesis (Surazynski et al. 2008).
It is well known that the breakdown of tissue barriers is
catalyzed by proteolytic enzymes released from the pri-
mary tumor (Duffy 1996). The ECM composed of colla-
gens, proteoglycans, and glycoproteins is a major barrier
against the invasion of tumor cells. Therefore, a tumor
progression critically depends on the breakdown of colla-
gen and other ECM proteins (Kleiner and Stetler-Stevenson
1999). MMPs are one of the most important enzymes for
the breakdown of ECM proteins. Although serum prolidase
activity is well documented in certain cancers, the exact
cause is still unknown (Palka et al. 2002; Karna et al. 2000;
Cechowska-Pasko et al. 2006; Arioz et al. 2009; Guszczyn
and Sobolewski 2004; Camuzcuoglu et al. 2009). Some
authors found that increased prolidase activities in cancer
such as lung (Karna et al. 2000), breast (Cechowska-Pasko
et al. 2006), endometrial cancer (Arioz et al. 2009),
stomach cancer (Guszczyn and Sobolewski 2004), and
ovarian cancer (Camuzcuoglu et al. 2009). In contrast,
Palka et al. (2002) demonstrated that prolidase activity in
pancreatic cancer was decreased. On the other hand, Yo-
shimura et al. (2004) investigated the urinary ECM mea-
surement in urine from patients with bladder cancer. They
have found that urinary ECM levels were higher in bladder
cancer groups than normal bladder groups.
In the present study, we found that patients with bladder
cancer had signiﬁcantly higher serum prolidase activities
than healthy controls. To the best of our knowledge, serum
prolidase activity has not been evaluated in bladder cancer.
This is the ﬁrst report investigating serum prolidase activity
in patients with bladder cancer.
Prolidase and the regulation of prolidase by NO may be
important in the regulation of collagen turnover. Collagen,
the most abundant protein in the body, constitutes more
than a quarter of total body proteins. NO has been shown to
play a role in regulating collagen metabolism. High NO
concentrations are associated with increased collagen bio-
synthesis and modiﬁcation (Mei et al. 2002). Surazynski
et al. 2005 demonstrate that NO stimulates prolidase
activity by increasing serine/threonine phosphorylation.
High concentrations of NO can inhibit cell growth and
Table 1 Demographic characteristics of the two groups in this study
Parameters Controls
(n = 32)
Patients
(n = 35)
P
Age (year) 62.8 ± 4.8 63.5 ± 3.4 ns
Body mass index (kg/m
2) 23.42 ± 2.14 22.11 ± 1.16 ns
Values are mean ± SD
ns non-signiﬁcant
Table 2 Prolidase activity, nitric oxide, oxidative and antioxidant
levels in bladder cancer and controls
Parameters Controls
(n = 32)
Patients
(n = 35)
P
TAS (mmol Trolox Equiv./l) 2.5 ± 0.2 1.1 ± 0.1 0.05
MDA (nmol/ml) 9.1 ± 0.4 16.8 ± 1.6 0.05
NO (lmol/l) 8.1 ± 0.8 17.1 ± 1.4 0.05
Prolidase (U/l) 25.4 ± 3.2 54.8 ± 4.3 0.05
Values are mean ± SD
TAS total antioxidant status, NO nitric oxide, MDA malondialdehyde
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123induce apoptosis in tumor cells (Cui et al. 1994). It has
been suggested that NO plays an important role in tumor
biology, with both tumor promoter and antitumor activity
(Eijan et al. 1998). It has been reported that continuous NO
production may be involved in the inﬂammatory process
associated with the appearance of many human malignan-
cies, including bladder cancer (O’Byrne and Dalgleish
2001). Furthermore, it has been reported that NO is ele-
vated in the urine from patients with bladder cancer (Eijan
et al. 2002). However, Bukan et al. (2003) did not observed
any signiﬁcant difference in serum total nitrite levels of the
patients with bladder cancer and control subjects. In the
present study, we found a signiﬁcantly increased serum NO
levels in patients with bladder cancer than in control
subjects.
It is known that the harmful effects of ROS are
controlled by various cellular defense systems consisting
of enzymatic (catalase, glutathione peroxidase, superox-
ide dismutase etc.) and non-enzymatic (vitamins E, C,
glutathione etc.) components (Mates et al. 1999). Epi-
demiological studies reveal that low levels of antioxi-
dants are associated with an increased risk of cancer.
Antioxidant depletion in the circulation may be due to
the scavenging of lipid peroxides as well as sequestration
by tumor cells (Sharma et al. 2007). However, if these
systems are insufﬁcient, severe metabolic malfunctions
and oxidative damage to DNA may result, which,
experimental studies in animals and in vitro have sug-
gested, are an important factor in carcinogenesis (Mar-
nett 2000). In the present study, we found a signiﬁcantly
decreased serum TAS levels in bladder cancer patients
than in control subjects.
On the other hand, MDA, the major aldehyde end
product of lipid peroxidation of membrane polyunsaturated
fatty acids by free radicals, is an indicator of oxidative
stress (Marnett 2000). In the present study, we found a
signiﬁcantly increased serum MDA levels in patients with
bladder cancer than in control subjects. This is compatible
with the results of two independent studies carried out by
Yalcin et al. (2004) and Kaczmarek et al. (2001). More-
over, increased levels of lipid peroxidation have been
reported in various malignant tumors including cervix
(Beevi et al. 2007), prostate (Ozmen et al. 2006), breast
(Tas et al. 2005) and lung (Gonenc et al. 2001).
Our results suggest that enhanced collagen turnover may
occur in patients with bladder cancer. Increased prolidase
seems to be associated with increased NO levels and oxi-
dative stress along with decreased antioxidant levels in
bladder cancer. Therefore, increased prolidase activity
may, in part, play a role in the pathogenesis of bladder
cancer. It is believed that the administration of antioxidant
vitamins such as A, C, and E may be useful in preventing
and treating bladder cancer.
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